Product Information
BRIMONIDINE 0.33% GEL PUMP is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $13.9261 per GM under NDC 45802007830. Its NADAC has been published 146 times since Dec 20, 2023.
FDA first approved this application on Sep 23, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802007830
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
BRIMONIDINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA209158FDA Approved
9/23/2021
TE Code
AB
On Market Since
1/1/2023
Pharmacological Classes
Price Statistics
The NADAC for BRIMONIDINE 0.33% GEL PUMP has been published 146 times since Dec 20, 2023, and over the history we have for it it has declined 4.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.9261 per GM |
|---|---|
| All-time high | $14.6308 (Apr 10, 2024) |
| All-time low | $10.4471 (Jul 17, 2024) |
| 52-week high | $14.4958 |
| 52-week low | $13.6708 |
| Median price | $13.7173 |
| Average price | $13.2906 |
| Largest weekly change | -14.6% (Jul 17, 2024) |
| Weeks tracked | 146 |
| Tracking since | Dec 20, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the brimonidine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
brimonidine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BRIMONIDINE 0.33% GEL PUMP?
The current National Average Drug Acquisition Cost (NADAC) for BRIMONIDINE 0.33% GEL PUMP, manufactured by Padagis Israel Pharmaceuticals Ltd, is $13.9261 per GM (NDC 45802007830), effective Sep 30, 2026.
How has the price of BRIMONIDINE 0.33% GEL PUMP changed over time?
Over the history we have for it, the NADAC for BRIMONIDINE 0.33% GEL PUMP has declined 4.8%. It has been tracked across 146 weekly CMS publications since Dec 20, 2023.
What are the highest and lowest recorded NADAC prices for BRIMONIDINE 0.33% GEL PUMP?
Since Dec 20, 2023, the NADAC for BRIMONIDINE 0.33% GEL PUMP has ranged from a low of $10.4471 (Jul 17, 2024) to a high of $14.6308 (Apr 10, 2024), with a median of $13.7173 per GM.
Are there cheaper alternatives to BRIMONIDINE 0.33% GEL PUMP?
No other NADAC-published product currently shares the active ingredient and strength of BRIMONIDINE 0.33% GEL PUMP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BRIMONIDINE 0.33% GEL PUMP?
BRIMONIDINE 0.33% GEL PUMP (NDC 45802007830) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.